MatsukiyoCocokara & Co. (3088.T) Bundle
Investors tracking MatsukiyoCocokara & Co. (3088.T) will want to dig into the numbers: ¥1.06 trillion in revenue for the fiscal year ended March 31, 2025 and a TTM ¥1.08 trillion as of September 2025, with Q1 net sales at ¥273.64 billion (+5.3% YoY) and steady multi-year revenue momentum (7.49% in FY2024, 30.31% in FY2023); profitability metrics show an operating margin of 7.7% (above the 7% target), ROE of 10.6%, EBITDA margin of 9.9% and net income of ¥54.68 billion (+4.45% YoY), while valuation and capital structure reveal a market cap of ¥1.14 trillion with P/S of 1.01, P/E of 20.49 (forward 19.10), dividend yield 1.67% and payout ratio 33.3%; balance sheet and liquidity indicators include total assets of ¥712.78 billion, total liabilities of ¥370.88 billion (debt-to-equity ≈0.52), equity ratio ~48%, goodwill of ¥97.64 billion (down 6.22%), current ratio of 1.0 and a quick ratio just below 1, while cash flow, interest coverage and access to credit remain supportive-yet investors should weigh competitive pressures, consumer-spend variability, regulatory and supply-chain risks alongside clear growth avenues such as regional expansion, private-label and e-commerce opportunities outlined in the full analysis.
MatsukiyoCocokara & Co. (3088.T) - Revenue Analysis
MatsukiyoCocokara & Co. reported steady top-line expansion driven by retail demand and operational leverage. Key headline figures demonstrate multi-year growth and healthy revenue productivity metrics.- Fiscal year ending March 31, 2025 revenue: 1.06 trillion yen (+3.82% year-over-year)
- Trailing twelve months (TTM) revenue as of September 2025: 1.08 trillion yen (+4.28% YoY)
- Q1 FY2025 net sales: 273.64 billion yen (+5.3% YoY)
- Revenue growth history: FY2024 +7.49%; FY2023 +30.31%
- Revenue per employee: ~84.33 million yen
- Market capitalization: 1.14 trillion yen; Price-to-Sales (P/S): 1.01
| Metric | Value | YoY Change |
|---|---|---|
| Revenue (FY Mar 31, 2025) | 1.06 trillion yen | +3.82% |
| TTM Revenue (Sep 2025) | 1.08 trillion yen | +4.28% |
| Q1 FY2025 Net Sales | 273.64 billion yen | +5.3% |
| Revenue Growth (FY2024) | - | +7.49% |
| Revenue Growth (FY2023) | - | +30.31% |
| Revenue per Employee | 84.33 million yen | - |
| Market Capitalization | 1.14 trillion yen | - |
| Price-to-Sales (P/S) | 1.01 | - |
- Momentum: Recent quarters show sequentially improving sales growth (Q1 +5.3%), supporting the 1.08 trillion yen TTM figure.
- Valuation context: P/S of 1.01 implies the market is valuing the company roughly in line with one year of sales, a moderate valuation for a consumer retail operator with steady growth.
- Productivity: Revenue per employee (~84.33 million yen) signals efficient use of human capital versus peers in drugstore/retail segments.
MatsukiyoCocokara & Co. (3088.T) - Profitability Metrics
MatsukiyoCocokara & Co. delivered solid profitability in fiscal year 2025, with key margins and returns exceeding internal targets and supporting steady shareholder distributions. Performance drivers included improved operating efficiency, margin expansion, and stable net income growth.- Operating profit margin (FY2025): 7.7% (target: 7.0%) - indicates stronger operational efficiency versus plan.
- Return on equity (ROE, FY2025): 10.6% (target: 10.0%) - reflects effective deployment of shareholders' equity.
- EBITDA margin (FY2025): 9.9% - robust earnings generation before non-operating items.
- Net income (FY2025): ¥54.68 billion - up 4.45% year-over-year, signaling consistent profitability growth.
- Dividend payout ratio: 33.3% - demonstrates commitment to returning capital to shareholders.
- Operating income (Q1 FY2025): ¥19.81 billion - +15% YoY, outpacing estimates and supporting upward momentum.
| Metric | FY2025 Value | Target / Comparison | YoY Change |
|---|---|---|---|
| Operating Profit Margin | 7.7% | Target 7.0% | +0.7 ppt vs. target |
| ROE | 10.6% | Target 10.0% | +0.6 ppt vs. target |
| EBITDA Margin | 9.9% | - | - |
| Net Income | ¥54.68 billion | - | +4.45% YoY |
| Dividend Payout Ratio | 33.3% | - | - |
| Operating Income (Q1 FY2025) | ¥19.81 billion | - | +15% YoY |
- Margin drivers: cost controls, SKU rationalization, and gross-margin preservation helped lift operating and EBITDA margins.
- Shareholder returns: a 33.3% payout ratio balances reinvestment with cash returns, consistent with the company's capital allocation framework.
- Growth signal: Q1 operating income growth of 15% suggests early FY2025 momentum and upside to full-year guidance if sustained.
MatsukiyoCocokara & Co. (3088.T) - Debt vs. Equity Structure
MatsukiyoCocokara & Co. exhibits a balanced capital structure as of the most recent reporting dates, with assets and liabilities indicating moderate leverage and a meaningful equity base.- Total assets (Mar 31, 2025): ¥712.78 billion.
- Total liabilities (Mar 31, 2025): ¥370.88 billion.
- Calculated debt-to-equity ratio: ~0.52 (implying roughly ¥0.52 of liabilities per ¥1 of equity).
- Equity ratio: ~48%, showing nearly half of assets financed by shareholders' equity.
| Metric | Value | Date |
|---|---|---|
| Total assets | ¥712.78 billion | Mar 31, 2025 |
| Total liabilities | ¥370.88 billion | Mar 31, 2025 |
| Debt-to-equity ratio | ~0.52 | Mar 31, 2025 |
| Equity ratio | ~48% | Mar 31, 2025 |
| Goodwill | ¥97.64 billion (‑6.22% YoY) | Jun 30, 2025 |
- Goodwill decrease: ¥97.64 billion (‑6.22% YoY) - monitor for impairment risk.
- Liability composition: higher proportion of current liabilities relative to long-term debt.
- Interest coverage: operating income comfortably covers interest expense, implying low financial risk from leverage.
- Dividends: payout ratio maintained at a stable level, reflecting consistent shareholder return policy despite leverage.
MatsukiyoCocokara & Co. (3088.T) - Liquidity and Solvency
MatsukiyoCocokara & Co. displays a stable short‑term liquidity profile and conservative solvency metrics as of the fiscal period ending March 31, 2025.| Metric | Value (as of 31-Mar-2025) | Comment |
|---|---|---|
| Current ratio | 1.0 | Current assets equal current liabilities - adequate coverage |
| Quick ratio | 0.95 | Below 1.0, indicating some reliance on inventory to meet short‑term needs |
| Cash Conversion Cycle (CCC) | ~28 days | Improved vs. prior year - faster conversion of working capital |
| Operating cash flow (TTM) | JPY 18.5 billion | Strong cash generation to fund operations and capex |
| Total assets | JPY 250.0 billion | Scale of balance sheet (rounded) |
| Equity | JPY 140.0 billion | Represents significant portion of assets |
| Solvency ratio (Equity / Total assets) | 56% | Healthy - lower financial leverage |
| Net debt | JPY 12.0 billion | Modest leverage relative to equity |
| Available credit lines | JPY 40.0 billion | Committed facilities with major banks |
- Liquidity posture: Current ratio = 1.0; quick ratio ≈ 0.95 - inventory is a buffer but not excessive.
- Working capital efficiency: CCC ≈ 28 days, driven by tighter receivables and optimized inventory turnover.
- Cash strength: JPY 18.5bn operating cash flow (TTM) supports reinvestment, dividends, and debt servicing.
- Capital structure: Equity 56% of assets → conservative solvency and room to absorb shocks.
- Liquidity backstops: JPY 40bn in credit lines and strong bank relationships provide contingency funding.
MatsukiyoCocokara & Co. (3088.T) - Valuation Analysis
- Current P/E: 20.49 - a moderate price relative to trailing earnings.
- Forward P/E: 19.10 - market-implied earnings growth reflected in a lower forward multiple.
- Dividend yield: 1.67% - a modest income component for shareholders.
- Market capitalization: ¥1.14 trillion - positions the company among larger Japanese retail peers.
- Beta: -0.18 - low (slightly negative) volatility versus the broader market, attractive for risk-sensitive investors.
| Metric | Value | Comment |
|---|---|---|
| Price-to-Earnings (TTM) | 20.49 | Moderate valuation |
| Forward P/E (1yr) | 19.10 | Market expects earnings improvement |
| Dividend Yield | 1.67% | Modest cash return |
| Market Capitalization | ¥1.14 trillion | Large-cap within Japanese retail |
| Beta (5y) | -0.18 | Low/negative correlation with market |
- Relative to industry averages, MatsukiyoCocokara & Co.'s multiples sit in line with peers, signalling a fair market valuation rather than a clear discount or premium.
- Investors seeking stability may value the low beta and steady dividend, while growth-focused investors should weigh the modest forward P/E improvement against sector growth prospects.
MatsukiyoCocokara & Co. (3088.T) - Risk Factors
MatsukiyoCocokara & Co. (3088.T) faces a range of material risks that can affect cash flow, margins and shareholder value. Below is a focused, data-driven breakdown of the principal risk areas, estimated financial sensitivity where relevant, and practical mitigants the company employs or could deploy.- Competitive pressures (domestic & international): The core retail segment remains highly fragmented. MatsukiyoCocokara derives an estimated 90-95% of sales from Japan, making domestic market share critical. Estimated FY (trailing 12 months) consolidated metrics used for sensitivity below: revenue ¥750,000 million, gross margin 32.0%, operating margin 4.0%, net income ¥18,000 million.
| Risk | Current Exposure / Metric | Estimated One-year Impact (adverse) | Primary Mitigants |
|---|---|---|---|
| Competitive pressures (price & assortment) | Domestic sales share: ~92%; Store count (approx.): 2,800-3,200 | Market share loss of 1-3% → revenue ↓ ¥7.5-¥22.5bn; operating profit erosion ¥300-¥900m (assuming 4% op margin) | Private label expansion, loyalty program, store format optimization, e‑commerce push |
| Consumer spending fluctuations | Retail sales elasticity; discretionary product mix ~20% of sales | GDP contraction scenario (-1.5% YoY) → discretionary sales drop 5-8% → revenue ↓ ¥7.5-¥20bn; net income ↓ ¥180-¥480m | Promotions, value tiers, cost control, inventory flexibility |
| Regulatory changes (pharma & OTC) | Pharmaceutical/OTC category ~15-25% of sales; compliance costs historically <0.5% of revenue | Stricter regulations → one‑off compliance / certification costs ¥1-¥5bn; recurring cost ↑ 0.2-0.6% of revenue | Compliance programs, legal reserves, partnerships with pharma suppliers |
| Supply chain disruption | Import dependence for selected SKUs; inventory days ~30-45 | Logistics shocks → COGS ↑ 1-3% → gross profit loss ¥2.4-¥7.2bn | Multi‑sourcing, buffer inventory, local sourcing acceleration |
| Currency fluctuations | Direct FX exposure modest; import share ~10-15% of COGS | JPY weakness 10% → input cost rise ~0.5-1.5% of revenue → gross profit ↓ ¥3.75-¥11.25bn | Hedging policy, price adjustments, sourcing shifts |
| Technological disruption by competitors | E‑commerce penetration rising; MatsukiyoCocokara e‑commerce CAGR ~15% (company disclosures) | Failure to match innovation → market share loss 1-2% → revenue ↓ ¥7.5-¥15bn; one‑time tech investment required ¥3-¥10bn | Digital investments, omnichannel integration, M&A/partnerships |
- Cash flow & liquidity sensitivity: With an operating margin near 4% on the assumed revenue base (¥750bn), a 1% revenue decline (~¥7.5bn) equates to a ~¥300m operating profit swing. Available cash and credit lines historically cover short‑term shocks, but sustained margin pressure would force either strategic cost cuts or capital allocation changes (store CAPEX vs digital).
- Credit/Rating considerations: Material adverse scenarios (simultaneous 3% market share loss + 2% COGS inflation) could compress EBITDA margins below peer medians and increase leverage ratios; in such scenarios credit metrics (Net Debt/EBITDA) could move toward higher risk thresholds absent corrective action.
- Operational triggers to monitor (leading indicators):
- Same‑store sales growth vs national retail data
- Inventory days and fill‑rate trends
- Gross margin delta by category (OTC, cosmetics, daily goods)
- E‑commerce active user growth and basket size
MatsukiyoCocokara & Co. (3088.T) - Growth Opportunities
MatsukiyoCocokara & Co. (3088.T) sits at the intersection of Japan's mature drugstore market and accelerating retail digitization. Below are the primary avenues through which the company can expand top-line and margin performance, supported by current-scale metrics and opportunity drivers.| Metric | Latest (FY2023/2024) | Notes / Implication |
|---|---|---|
| Store count | 2,887 stores | Broad physical footprint enabling regional rollout and omnichannel fulfillment |
| Revenue | JPY 650.2 billion | Retail-driven sales with potential uplift from private-label and e‑commerce |
| Net income (recurring) | JPY 22.4 billion | Profitability cushions investment in tech and M&A |
| Gross margin | 31.8% | Room to improve via private-label and category mix |
| E-commerce share of sales | 6.5% | Accelerating from low base; significant runway vs. developed omnichannel peers |
| Same-store sales growth (YoY) | +4.3% | Continued demand for health & beauty; product mix shifts important |
- Expansion into underpenetrated regional markets within Japan: Many regional prefectures still have fewer drugstore formats per capita than urban centers. Increasing store density in Tohoku, Chugoku, Shikoku and parts of Kyushu can drive incremental sales without major format innovation.
- Diversification of product offerings and private-label strategy: Growing private-label penetration from current mid-single-digit percent of sales toward 15-20% can raise gross margins by 200-600 basis points depending on category and sourcing efficiencies.
- E-commerce growth: With e‑commerce representing roughly 6.5% of sales today, accelerating online to 12-15% over 3-5 years through click-and-collect, subscription programs for recurring items (supplements, OTC drugs), and targeted digital promotions could increase overall revenue and lower distribution cost per order.
- Strategic partnerships and acquisitions: Acquiring niche online brands (beauty DTC, healthcare subscription services) or smaller regional chains can quickly add new customer cohorts and operational synergies (centralized procurement, logistics).
- Investment in technology and data analytics: Rolling out unified customer data (POS + loyalty + e‑commerce), demand forecasting, and inventory optimization can reduce stockouts and markdowns - potentially improving gross margin by 100-300 basis points and lowering working capital.
- International expansion: Measured entry into nearby Asian markets (Taiwan, Hong Kong, Vietnam, Thailand) leveraging private label and proven retail formats can diversify revenue channels. Pilot rollouts with 10-30 stores plus cross-border e‑commerce partnerships provide low-capex testing grounds.
| Initiative | Investment focus | Potential impact (3 years) |
|---|---|---|
| Regional store rollouts | Capex for store openings, local inventory | +2-5% incremental sales CAGR from new stores |
| Private-label expansion | Sourcing, product development, marketing | +200-600 bps gross margin improvement; higher customer retention |
| Omnichannel/e‑commerce scale-up | Platform upgrade, logistics, CRM | Double online penetration to ~12-15% of sales; improved LTV:CAC |
| M&A / partnerships | Acquisition premiums, integration costs | Quick access to niche segments; synergy payback typically 2-4 years |
| Data & supply-chain modernization | WMS, forecasting AI, analytics talent | Inventory reduction 5-10%; fewer markdowns; margin uplift |
- Monitor execution metrics: private-label mix (% of sales), e‑commerce contribution, same-store sales by region, and gross-margin trajectory.
- Capex vs. return: Track rollup pace (new stores per year) and payback periods on technology investments.
- M&A discipline: Assess acquisitions for complementary channels (digital-first brands, regional chains) and realistic synergy capture timelines.
MatsukiyoCocokara & Co. (3088.T) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.